Generate Biomedicines (GENB) Earnings Analysis
Generate Biomedicines (GENB) next reports earnings on 2026-08-06, consensus EPS -0.48 USD. Trailing P/E -2.79.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GENB next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.48 USD |
| Revenue estimate | 0.01B |
GENB earnings history — beats and misses
No reported earnings history is available for this symbol in our dataset.
GENB valuation and analyst view
| Trailing P/E | -2.79 |
|---|---|
| Trailing EPS | -4.0559 USD |
| Price / book | -1.13 |
| Dividend yield | 0.00% |
| Market cap | 1.79B |
| Analyst consensus | Buy (2 buy / 0 hold / 0 sell) |
| Avg price target | 23.5 USD |
Related research pages
Frequently asked questions
When is Generate Biomedicines (GENB)'s next earnings date?
Generate Biomedicines is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.48 USD and revenue estimate of 0.01B.
What is GENB's current P/E ratio and EPS?
GENB trades at a trailing P/E of -2.79 on trailing EPS of -4.055900731233658 USD.
What do analysts rate GENB?
Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 23.5 USD.